Advanced Oncotherapy PLC Exercise of Warrants and Issue of Equity (7181L)
September 09 2019 - 11:48AM
UK Regulatory
TIDMAVO
RNS Number : 7181L
Advanced Oncotherapy PLC
09 September 2019
9 September 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Exercise of Warrants and Issue of Equity
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that it today issued 2,400 new ordinary shares of 25
pence in the Company ("New Ordinary Shares") pursuant to the
exercise of warrants at an exercise price of 150 pence per share.
The New Ordinary Shares will rank pari passu in all respects with
the existing Ordinary Shares of the Company. The consideration for
the exercise of the warrants amounts to GBP3,600 which has been
received by the Company.
Application has been made for the 2,400 New Ordinary Shares to
be admitted to trading on AIM ("Admission") and it is expected that
Admission will occur on or about 13 September 2019.
Total voting rights
Following Admission, the Company's enlarged issued share capital
will comprise 230,228,494 ordinary shares of 25 pence each, with
one voting right per share ("Ordinary Shares"). The Company does
not hold any ordinary shares in treasury and therefore the total
number of Ordinary Shares with voting rights in the Company is
230,228,494.
The above figure of 230,228,494 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0)20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nominated Adviser
& Joint Broker)
Nick Athanas / Liz Kirchner / Nicholas Chambers Tel: +44 (0)20 3328
5656
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior Tel: +44 (0)20 7710 7600
Walbrook PR (Financial PR & Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com
IR)
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / Mob: +44
(0)7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the
treatment of cancer, which harnesses the very best in modern
technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva,
focuses on the development of a proprietary proton accelerator -
LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates
protons to the energy levels achieved in legacy machines but in a
compact and truly modular unit, offering significant cost
advantages. LIGHT also delivers proton beams in a way that
facilitates greater precision and electronic control, which are not
achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology, offering better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton or particle therapy and
actively seeks working relationships with providers of these
innovative technologies. Through these relationships, the Company
will remain the prime provider of cutting edge, cost-effective
systems for particle therapy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOELLMATMBIMBAL
(END) Dow Jones Newswires
September 09, 2019 11:48 ET (15:48 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024